pSivida’s collaborative partner, Alimera Sciences, Inc. “Alimera”, filed a Form S-1/A with the Securities & Exchange Commission which reported the 24 month results of the two Phase 3 pivotal clinical trials for Iluvien in the treatment of Diabetic Macular Edema. Alimera reported that based on these results, it plans to submit a New Drug Application to the Food and Drug Administration for approval of the low dose of Iluvien in the second quarter of 2010, followed by registration filings in various European countries and Canada; that it intends to request Priority Review of the NDA from the FDA; and that if Priority Review is granted, it can expect a response to its NDA from the FDA in the fourth quarter of 2010.

Last Trade: 4.23
Trade Time: Dec 24
Prev Close: 4.23
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 0.60 – 6.25
Volume: 0
Avg Vol (3m): 158,557
Market Cap: 77.38M

About pSivida Corp.

pSivida Corp., formerly pSivida Limited. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, the drug is released on a controlled and level basis for months or years. The Company has developed with partners two of the only three products approved by the United States Food and Drug Administration (FDA) for the long-term, sustained release delivery of drug to treat chronic eye disease, and a third partnered product is in late-stage Phase III clinical trials. Its Phase III partnered product, which utilizes the third-generation of its Durasert technology system, delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME). The Company has three technology systems: Durasert, BioSilicon and CODRUG. The Company’s lead BioSilicon product candidate, BrachySil, delivers therapeutic phosphorus-32, or P32, a radioactive form of phosphorus used to treat cancer, directly to solid tumors.